Short answer
iRhythm Holdings, Inc. (IRTC) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.2). $50 million settlement payment by iRhythm to Baxter, creating a significant near-term cash and earnings charge.
iRhythm Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $50 million settlement payment by iRhythm to Baxter, creating a significant near-term cash and earnings charge
- Mutual worldwide, royalty-free, fully paid-up patent licenses covering cardiac-monitoring sensor products and services
- Six-year mutual covenant not to sue, reducing patent-litigation risk and supporting commercial continuity
- Settlement resolves all outstanding litigation while restricting challenges to licensed patents unless enforcement occurs
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results covered the quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains the detailed financial results
- Results announcement dated August 6, 2026; investors should review Exhibit 99.1 for operating metrics
Item 7.01 · Regulation FD Disclosure
- Definitive agreement to acquire Vital Connect, Inc., signaling expansion through an inorganic growth transaction
- Transaction details and strategic rationale provided in Exhibit 99.2 press release
- Acquisition announcement may affect valuation, integration expectations, and future capital requirements
Item EX-99.1 · Exhibit EX-99.2
- Q2 revenue $224.2M, up 20.1%, with gross margin 72.8%, up 160 basis points
- Adjusted EBITDA $43.3M and margin 19.3%, improving $27.6M and 1,090 basis points year over year
- GAAP net loss narrowed to $0.4M from $14.2M, while adjusted net income reached $19.3M
- FY2026 guidance raised to revenue $880M–$890M and adjusted EBITDA margin 13.0%–14.0%
- VitalConnect acquisition valued at approximately $287.5M, expanding iRhythm’s cardiac-monitoring addressable market subject to closing risks
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other iRhythm Holdings, Inc. 8-K filings
Get the next IRTC 8-K as it lands
Follow IRTC for push alerts, or ask the research agent what this filing means.